Skip to main content
ChemPartner PharmaTech Co., Ltd. logo

ChemPartner PharmaTech Co., Ltd. — Investor Relations & Filings

Ticker · 300149 ISIN · CNE100000Y27 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 2,256 across all filing types
Latest filing 2018-01-12 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 300149

About ChemPartner PharmaTech Co., Ltd.

https://www.chempartner.com

ChemPartner PharmaTech Co., Ltd. is a global research and development organization providing comprehensive drug discovery and development services. Operating as a Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO), the company supports pharmaceutical and biotechnology clients through an integrated service platform. Core capabilities include medicinal chemistry, biology, pharmacology, drug metabolism and pharmacokinetics (DMPK), and toxicology. The organization also offers specialized expertise in biologics discovery, protein engineering, and antibody development. ChemPartner facilitates the transition from early-stage research to clinical development through its pharmaceutical development and manufacturing capabilities, utilizing advanced technology to accelerate the discovery and production of novel therapeutic agents.

Recent filings

Filing Released Lang Actions
独立董事关于第三届董事会第三十九次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent director's opinion on a major asset restructuring matter to be discussed at the company's 39th board meeting of the third session. It discusses the decision-making process, the restructuring plan, legal compliance, and the use of raised funds. The document is focused on governance and approval of a significant transaction rather than presenting financial statements or audit results. It is not a full annual or interim report, nor an earnings release or audit report. It is also not a simple announcement or certification but a detailed governance-related opinion on a board matter. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of board decisions and management matters related to company governance and major transactions.
2018-01-12 Chinese
董事会关于本次重大资产重组事项履行法定程序的完备性、合规性及提交法律文件的有效性的说明
Capital/Financing Update Classification · 95% confidence The document is a detailed explanation from the board of directors of Quantum Hi-Tech (China) Biological Co., Ltd. regarding the completeness, compliance, and validity of legal documents submitted for a major asset restructuring transaction. It discusses the legal procedures followed, regulatory compliance, board meetings, and approvals related to the issuance of shares and cash payment to purchase assets. The content focuses on the procedural and legal aspects of a significant asset acquisition and restructuring, including references to relevant laws and regulations, board resolutions, and disclosure obligations. It is not a full financial report, earnings release, or audit report, but rather a formal announcement and explanation related to a major transaction and its legal compliance. This fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes, including major asset acquisitions and restructuring.
2018-01-12 Chinese
第三届董事会第三十九次会议决议公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement of resolutions from the 39th meeting of the 3rd Board of Directors of Quantum Hi-Tech (China) Biological Co., Ltd. It discusses approval of a major asset restructuring involving issuance of shares and cash payment to purchase 90% equity of a target company, including detailed terms, pricing, voting results, legal compliance, and regulatory approvals. The content focuses on the board's deliberations and approvals related to a significant capital and asset transaction, including compliance with the China Securities Regulatory Commission and Shenzhen Stock Exchange rules. It is not a full annual or quarterly financial report, nor an earnings release or audit report. It is not a simple announcement of voting results but a comprehensive board resolution document on a capital/financing transaction. Therefore, the document best fits the category of Capital/Financing Update (CAP).
2018-01-12 Chinese
关于提供资料真实、准确、完整的承诺函（二）
Regulatory Filings Classification · 95% confidence The document is a commitment letter from the company's directors, supervisors, and senior management regarding the accuracy and completeness of information provided for a transaction involving the acquisition of a 90% stake in another company. It includes personal signatures and legal commitments related to disclosure and compliance during the restructuring process. There are no financial statements, audit opinions, or report data. The document is a formal attestation or certification related to a transaction, not a financial report or announcement of voting results. It fits best under Regulatory Filings (RNS) as it is a legal and compliance-related filing without substantive financial data or report content.
2018-01-12 Chinese
董事会关于是否达到中国证监会《关于规范上市公司信息披露及相关各方行为的通知》第五条相关标准的说明
Regulatory Filings Classification · 95% confidence The document is a statement from the board of directors of Quantum Hi-Tech (China) Biological Co., Ltd. regarding whether the stock price fluctuations before a trading suspension meet the criteria set by the China Securities Regulatory Commission (CSRC) in its notice on regulating information disclosure and related behaviors. It discusses stock price movements, index comparisons, and concludes that the price fluctuations did not constitute abnormal movements under the relevant CSRC rules. The document is a regulatory compliance disclosure related to stock price behavior and trading suspension, not a financial report, earnings release, or management discussion. It is a regulatory announcement explaining compliance with CSRC rules, fitting best under Regulatory Filings (RNS). The document length is short (1199 characters), and it is not an announcement of a report publication but a standalone compliance explanation.
2018-01-12 Chinese
关于提供资料真实、准确、完整的承诺函（一）
Regulatory Filings Classification · 95% confidence The document consists of multiple commitment letters from various shareholders and entities involved in a transaction where Quantum Hi-Tech (China) Biological Co., Ltd. plans to acquire 90% equity of Shanghai Ruizhi Chemical Research Co., Ltd. The letters are assurances regarding the accuracy, completeness, and truthfulness of information provided for the transaction, and commitments to disclose information timely and lock shares if investigations arise. There is no financial data, no report or presentation, no voting results, no management or board changes, no earnings or audit information. The document is a legal and regulatory commitment related to a merger/acquisition transaction but does not itself constitute a merger announcement or proxy statement. It is a regulatory filing related to the transaction, primarily a legal commitment letter. Therefore, the best fitting category is Regulatory Filings (RNS).
2018-01-12 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.